Gilead (GILD) was a leading biotech in the fight against HIV, posting tremendous annual growth in sales and profits. Sales grew at least 26% every year last decade. Yet this former highflyer has surely matured as sales are growing in the high single-digits these days.
But sales and profit growth rates could move back into the low teens by the middle of the decade thanks to a robust pipeline of cardio-pulmonary drugs. Gilead's HIV franchise also has plenty of life left in it as key drugs get tweaked to boost efficacy.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV